Usefulness of plasminogen activator inhibitor-1 as a predictive marker of mortality in sepsis

Journal of Intensive Care

Volumn 5, Issue 1, 2017, Pages

  Hoshino, Kota ^a   Kitamura, Taisuke ^a   Nakamura, Yoshihiko ^a   Irie, Yuhei ^a   Matsumoto, Norihiko ^a   Kawano, Yasumasa ^a   Ishikura, Hiroyasu ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

Disseminated intravascular coagulation; Fibrinolysis; Pathogen associated molecular patterns; Sepsis 3

Indexed keywords

ANTITHROMBIN; BIOLOGICAL MARKER; FIBRIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; THROMBOMODULIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CONSCIOUSNESS; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; ENZYME IMMUNOASSAY; FEMALE; FIBRINOLYSIS; HUMAN; INTENSIVE CARE UNIT; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; MICROTHROMBUS; MIDDLE AGED; MORTALITY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEPSIS; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SURVIVAL RATE;

EID: 85021947807     PISSN: None     EISSN: 20520492     Source Type: Journal    
DOI: 10.1186/s40560-017-0238-8     Document Type: Article

References (26)

1. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302:2323-9.
2. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006;34:344-53.
3. Wittebole X, Castanares-Zapatero D, Laterre PF. Toll-like receptor 4 modulation as a strategy to treat sepsis. Mediators Inflamm. 2010;2010:568396.
4. Endo S, Suzuki Y, Takahashi G, Shozushima T, Ishikura H, Murai A, et al. Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. J Infect Chemother. 2012;18:891-7.
5. Shozushima T, Takahashi G, Matsumoto N, Kojika M, Okamura Y, Endo S. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother. 2011;17:764-9.
6. Ulla M, Pizzolato E, Lucchiari M, Loiacono M, Soardo F, Forno D, et al. Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department: a multicenter prospective study. Crit Care. 2013;17:R168.
7. Ito T. PAMPs and DAMPs as triggers for DIC. J Intensive Care. 2014;2:67.
8. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13:34-45.
9. Gando S, Otomo Y. Local hemostasis, immunothrombosis, and systemic disseminated intravascular coagulation in trauma and traumatic shock. Crit Care. 2015;19:72.
10. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA. 1995;273:117-23.
11. Dhainaut JF, Yan SB, Joyce DE, Pettilä V, Basson B, Brandt JT, et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost. 2004;2:1924-33.
12. Kienast J, Juers M, Wiedermann CJ, Hoffmann JN, Ostermann H, Strauss R, et al. KyberSept investigators: treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost. 2006;4:90-7.
13. Beale R, Reinhart K, Brunkhorst FM, Dobb G, Levy M, Martin G, et al. Promoting global research excellence in severe sepsis (PROGRESS): lessons from an international sepsis registry. Infection. 2009;37:222-32.
14. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315:801-10.
15. Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K, et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med. 2006;34:625-31.
16. Vincent JL, de Mendonça A, Cantraine F, Moreno R, Takala J, Suter PM, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26:1793-800.
17. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine Chest. 1992;101:1644-55.
18. Clec'h C, et al. Diagnostic and prognostic value of procalcitonin in patients with septic shock. Crit Care Med. 2004;32:1166-9.
19. Jensen JU, et al. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med. 2006;34:2596-602.
20. Masson S, et al. Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality in sepsis: data from the Albumin Italian Outcome Sepsis trial. Crit Care. 2014;18:R6.
21. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood. 1987;69:381-7.
22. Fujishima S, Gando S, Saitoh D, Mayumi T, Kushimoto S, Shiraishi S, et al. A multicenter, prospective evaluation of quality of care and mortality in Japan based on the Surviving Sepsis Campaign guidelines. J Infect Chemother. 2014;20:115-20.
23. Asakura H. Classifying types of disseminated intravascular coagulation: clinical and animal models. J Intensive Care. 2014;2:20.
24. Koyama K, Madoiwa S, Nunomiya S, Koinima T, Wada M, Sakata A, et al. Combination of thrombin-antithrombin complex, plasminogen activator inhibitor-1, and protein C activity for early identification of severe coagulopathy in initial phase of sepsis: a prospective observational study. Crit Care. 2014;18:R13.
25. Madoiwa S, Nunomiya S, Ono T, Shintani Y, Ohmori T, Mimuro J, et al. Plasminogen activator inhibitor 1 promotes a poor prognosis in sepsis-induced disseminated intravascular coagulation. Int J Hematol. 2006;84:398-405.
26. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707-10.